Immunological sequestration of ALK1 ligands (using ALK1-Fc) or antibody against ALK1 have been reported to inhibit tumor angiogenesis and tumor growth in mouse models of pancreatic cancer, breast cancer, and melanoma (Roman and Hinck, 2017). Here, ACVRL1 is linked to familial pancreatic carcinoma.